# Liquidia Corporation Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-first-quarter-2026-financial-results
Ticker: LQDA
Company: Liquidia Corporation
Source: Liquidia Corporation
Published: 2026-05-11 10:30 EST
Original Source URL: https://www.liquidia.com
## Summary

YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of

## Article Body
YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of
## Recent Company News
- 2026-05-27 12:30 EST — [Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-present-at-2026-jefferies-global-healthcare-conference) — Source: Liquidia Corporation
- 2026-05-11 10:30 EST — [Liquidia Corporation Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-first-quarter-2026-financial-results) — Source: Liquidia Corporation
- 2026-05-06 12:30 EST — [Liquidia Corporation to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-participate-in-upcoming-investor-conferences) — Source: Liquidia Corporation
- 2026-05-04 12:30 EST — [Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026](https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-report-first-quarter-2026-financial-results-on-may-11-2026) — Source: Liquidia Corporation
- 2026-03-05 11:30 EST — [Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Liquidia Corporation
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)